Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.2% |
| 2 | Technology | 14.19% |
| 3 | Financials | 12.33% |
| 4 | Consumer Staples | 10.22% |
| 5 | Industrials | 9.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ICAD
2251
DELISTED
iCAD Inc
ICAD
| $2.05M | ﹤0.01% |
490,160
-11,400
| -2% | -$54.8K |
|
|
EGAS
2252
DELISTED
Gas Natural Inc.
EGAS
| $2.05M | ﹤0.01% |
158,900
-107,600
| -40% | -$1.36M |
|
2253
Kamada
KMDA
$435M
| $2.05M | ﹤0.01% |
342,200
+77,400
| +29% | +$550K |
|
|
CDMO
2254
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
| $2.05M | ﹤0.01% |
481,150
+41,485
| +9% | +$170K |
|
|
DSKE
2255
DELISTED
Daseke, Inc. Common Stock
DSKE
| $2.04M | ﹤0.01% |
+183,300
| New | +$1.82M |
|
2256
United Parks & Resorts
PRKS
$2.06B
| $2.04M | ﹤0.01% |
125,260
-892,756
| -88% | -$15.3M |
|
2257
Cumberland Pharmaceuticals
CPIX
$118M
| $2.04M | ﹤0.01% |
290,853
+20,613
| +8% | +$136K |
|
|
JNP
2258
DELISTED
Juniper Pharmaceuticals, Inc. Common Stock
JNP
| $2.03M | ﹤0.01% |
401,600
+92,100
| +30% | +$412K |
|
2259
Frequency Electronics
FEIM
$855M
| $2.02M | ﹤0.01% |
211,616
+9,716
| +5% | +$97.8K |
|
2260
STAAR Surgical
STAA
$1.28B
| $2.02M | ﹤0.01% |
186,600
+42,300
| +29% | +$414K |
|
|
WPT
2261
DELISTED
World Point Terminals, LP
WPT
| $2.01M | ﹤0.01% |
116,330
+65,648
| +130% | +$1.11M |
|
2262
Limoneira
LMNR
$251M
| $2M | ﹤0.01% |
84,600
-3,600
| -4% | -$73.2K |
|
2263
Pluri
PLUR
$18.5M
| $2M | ﹤0.01% |
19,516
+93
| +0.5% | +$10.3K |
|
|
DCTH
2264
DELISTED
Delcath Systems Inc
DCTH
| $2M | ﹤0.01% |
10,141,607
+9,467,493
| +1,404% | +$692K |
|
2265
Identive
INVE
$63.4M
| $1.99M | ﹤0.01% |
378,048
+99,689
| +36% | +$567K |
|
|
ACFC
2266
DELISTED
Atlantic Coast Financial Corporation
ACFC
| $1.98M | ﹤0.01% |
253,100
-1,200
| -0.5% | -$9.29K |
|
2267
Companhia Siderúrgica Nacional
SID
$1.17B
| $1.98M | ﹤0.01% |
921,200
+640,600
| +228% | +$1.43M |
|
|
PGNX
2268
DELISTED
Progenics Pharmaceuticals Inc
PGNX
| $1.98M | ﹤0.01% |
291,489
+48,100
| +20% | +$355K |
|
2269
DMC Global
BOOM
$154M
| $1.98M | ﹤0.01% |
151,000
+5,000
| +3% | +$66.8K |
|
|
ILG
2270
DELISTED
ILG, Inc Common Stock
ILG
| $1.97M | ﹤0.01% |
71,815
-124,614
| -63% | -$3.16M |
|
2271
Royal Gold
RGLD
$19.5B
| $1.97M | ﹤0.01% |
+25,200
| New | +$1.9M |
|
|
LION
2272
DELISTED
Fidelity Southern Corporation
LION
| $1.97M | ﹤0.01% |
86,119
-153,350
| -64% | -$3.39M |
|
2273
POSCO
PKX
$17.8B
| $1.97M | ﹤0.01% |
31,400
-14,200
| -31% | -$855K |
|
2274
Consumer Portfolio Services
CPSS
$208M
| $1.96M | ﹤0.01% |
431,500
-50,900
| -11% | -$230K |
|
2275
Titan Machinery
TITN
$429M
| $1.96M | ﹤0.01% |
108,900
+68,900
| +172% | +$1.13M |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.